MarginsXMarginsX
Home › Markets › Health Care › IONS

Ionis Pharmaceuticals Inc. (IONS)

IONS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$28.01
-3.61% on the day
Market cap
$4.7B
Mid cap
Revenue · 2025
$943.7M
+33.8% on 2024
Net income · 2025
-$381.4M
-40.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/874015/000087401526000115/0000874015-26-000115-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerIONS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000874015
SEC industry codePharmaceutical Preparations
Incorporated inCA

Financials · 2025

LineValue
Revenue$943.7M
Net income-$381.4M
Operating income-$381.7M
Net margin-40.4%
Operating margin-40.4%
Revenue growth+33.8%
Cash$372.3M
Total assets$3.5B
P/E (computed)Net income was not positive
P/S (computed)4.9×

Warning signs

Cash runway
6.5 months
$296.3M cash at September 30, 2026
Share count, 1 year
+2.8%
2025-10-23 to 2026-11-03 · +16.1% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$144.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$296.3M cash; operating cash flow -$136.1M a quarter.Report 2026-09-30
Shares outstanding166,545,100 (2026-11-03); 161,974,393 a year earlier; 143,472,119 three years earlier.Cover page 2026-11-03
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1.1M, sold $145.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$242.7M-$110.0M-$179.4M$296.3M$0$960.1M10-Q 2026-11-09
Q2 2026
2026-06-30
$267.9M-$114.6M$565.5M$350.1M$0$874.1M10-Q 2026-07-29
Q1 2026
2026-03-31
$246.1M-$92.5M-$792.8M$173.4M$432.5M$1.1B10-Q 2026-04-29
Q4 2025
2025-12-31
$203.3M-$229.4M-$137.7M$372.3M$1.8B$943.7M10-K 2026-02-26
Q3 2025
2025-09-30
$156.7M-$128.6M-$131.4M$338.3M$630.9M$967.0M10-Q 2026-11-09
Q2 2025
2025-06-30
$452.0M$123.6M$151.3M$297.3M$630.1M$944.1M10-Q 2026-07-29
Q1 2025
2025-03-31
$131.6M-$146.9M-$150.8M$264.2MNo debt tags$717.3M10-Q 2026-04-29
Q4 2024
2024-12-31
$226.6M-$104.3M-$116.1M$242.1M$1.3B$705.1M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52024-09-10
Latest annual report
IONIS PHARMACEUTICALS, INC. 10-K 12-31-2025
10-K2026-02-26
Latest quarterly / interim
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)
10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 1,008 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-26.3%
1 month-31.4%
3 months-48.0%
Year to date-63.3%
1 year-58.4%
From 52-week high-66.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TVTXTravere Therapeutics Inc.$49.70-1.88%$4.8B
COGTCogent Biosciences Inc.$27.44-3.92%$4.8B
EWTXEdgewise Therapeutics Inc.$43.68-4.90%$4.8B
DNTHDianthus Therapeutics Inc.$89.55-2.46%$5.0B
LQDALiquidia Corporation$56.37-1.81%$5.1B
PTCTPTC Therapeutics Inc.$60.97-3.97%$5.1B
ERASErasca Inc.$15.11-3.51%$5.3B
TNGXTango Therapeutics Inc.$24.17-5.22%$4.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier